Introduction: GABA is a type of inhibitory neurotransmitter; it blocks or inhibits certain nerve transmission. Our nervous system is calmed by GABA, thus preventing excessive fear or anxiety is a simple and rapid approach to raise and maintain healthy mental health. Some medical conditions associated with a change in the level of GABA are anxiety and mood disorders, schizophrenia, autism spectrum disorder, depression, epilepsy, and seizures. The aim of this study to increase the activity of GABA which can be enhanced by the incorporation of anthracene, phthalimide, benzene, and thalidomide. Materials and methods: Insilico Docking study was carried out by using Auto Dock 4.0 against GABA-AT protein and the binding energy was found out to be -7.61kcal/mol. GABA-Phthalimide substitution, derivatives were designed as they possess a similar degree of anticonvulsant potency due to their phenytoin-like profile. The phthalimide pharmacophores interaction with voltage dependent sodium channels in neurons was investigated. Results and conclusion: This suggests the substitution of GABA as a possible lead compound. Therefore, in the present study, N, N-phthaloyl GABA combine with aniline a Noval compound 4-(1,3-dioxoisoindolin-2-yl)-N-phenylbutanamide is designed with improved anticonvulsant properties.
The main inhibitory neurotransmitter in the mammalian brain is 4-aminobutyric acid (GABA). Phthalimide acts as a sodium channel antagonist, one of the finest targets for treating epilepsy is the sodium channel and JNK kinase activity is inhibited to treat epilepsy. a novel compound with multiple targets of action for the treatment of epilepsy also anti-oxidant activity has been designed. The compounds are designed in two series aldehydes and aniline. Docking of all the designed compounds has been done with the suitable protein GABA-AT, sodium channel, JNK protein, and anti-oxidant from protein bank. QSAR was done for constructing many linear regression models. In combination with the developed Docking and QSAR outcomes, ADMET has been performed for the active compounds. The result shows that 11 of the compounds have excellent binding energy in docking with all the receptors and also have good QSAR results and follow the ADMET. The structural understanding of human GABA-AT inhibition was obtained from molecular dynamics simulation studies for compound no. 11 at 5 nanoseconds. Synthesis and pharmacological activity also suggest that the designed compound no.11 be considered the best Novel Compound.
22 January 2026 in Bulletin of the National Research Centre
Single-atom catalysts (SACs) have emerged as a powerful class of nano-catalysts for tumor therapy due to their well-defined active sites and exceptional ca
Chronic kidney disease (CKD) is a prevalent and complex disorder in the current clinical landscape. Adequate intake of essential micronutrients is required